Michael Schamroth insider trades: Biospecifics Technologies (BSTC) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Michael reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 24, 2014 | BSTC | ↓ Sell | 4,499 | $39.36 | $177K | Direct | Nov 25, 2014 (1d) |
| Nov 19, 2014 | BSTC | ↓ Sell | 5,000 | $39.09 | $195K | Direct | Nov 21, 2014 (2d) |
| Nov 17, 2014 | BSTC | ↓ Sell | 301 | $39.00 | $12K | Direct | Nov 19, 2014 (2d) |
| Nov 14, 2014 | BSTC | ↓ Sell | 5,200 | $39.20 | $204K | Direct | Nov 14, 2014 (0d) |
| Mar 17, 2008 | BSTC.PK | ↓ Sell | 50,000 | $11.90 | $595K | By M. Schamroth & Sons, a limited partne | Mar 26, 2008 (9d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Michael Schamroth's insider trades
Michael Schamroth is a director at Biospecifics Technologies (BSTC). Since Mar 17, 2008, Michael has reported no open-market purchases and 5 sales worth $1.2M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (8 filings), option exercises (7 filings), shares returned to the company (2 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BSTC insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.